Second Sight Medical Products Revenue and Competitors

Location

$136.8M

Total Funding

Estimated Revenue & Valuation

  • Second Sight Medical Products's estimated annual revenue is currently $45.9M per year.(i)
  • Second Sight Medical Products received $4.0M in venture funding in October 2018.
  • 0
  • Second Sight Medical Products's total funding is $136.8M.

Employee Data

    00

Second Sight Medical Products's People

NameTitleEmail/Phone
1
Director Financial ReportingReveal Email/Phone
2
Senior Director, Software EngineeringReveal Email/Phone
3
Director Quality Assurance and Regulatory AffairsReveal Email/Phone
4
Director, Implant R&DReveal Email/Phone
5
Director, Clinical and Scientific AffairsReveal Email/Phone
6
Senior Patent Counsel and Compliance OfficerReveal Email/Phone
7
Director ManufacturingReveal Email/Phone
8
Senior Vision Rehabilitation ManagerReveal Email/Phone
9
Customer Service ManagerReveal Email/Phone
10
Lead Test Technician ManufacturingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Second Sight Medical Products?

Second Sight's mission is to restore useful vision to the blind and visually impaired. Second Sight is the leader in neuromodulation devices to treat blindness, with the most advanced technology platform delivering groundbreaking artificial vision. The recognized leader in retinitis pigmentosa, the company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. Second Sight's Argus II retinal prosthesis system is an FDA and CE approved device that delivers durable, useful vision to people with severe to profound retinitis pigmentosa (RP). The Argus II has been implanted in over 300 patients worldwide, with proven durability beyond 10 years The Argus II is the standard of care for patients with severe RP, with over 25 exclusive regional centers offering the technology across North America The company is actively developing a cortical stimulation device that bypasses the diseased eye and has the potential to provide a new form of vision to individuals blinded due to a wide range of causes. If you would like to learn more about Second Sight® Medical Products or the Argus® II Retinal Prosthesis System, you can reach us at (800)350-7060.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$136.8M

Total Funding

N/A

Number of Employees

$45.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Second Sight Medical Products News

2022-04-20 - Electroceuticals Market Size, Scope And Forecast | Oticon ...

... ElectroCore LLC, Second Sight Medical Products Inc. This Electroceuticals Market report covers important market segments on the basis of...

2022-04-17 - Electroceuticals Market Size And Forecast | Oticon Medical ...

... Stimwave LLC, Cefaly Technology, MED-EL, BioElectronics Corporation, ElectroCore LLC, Second Sight Medical Products Inc.

2022-04-13 - Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®

(NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with...

2021-06-28 - Second Sight Medical Products : Announces Closing of Public Offering (Form 8-K)

Second Sight Medical Products Announces Closing of Public Offering Los Angeles, CA - (BUSINESS NEWSWIRE) June 25 , 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ('Second Sight' or the 'Company'), a leading developer of implantable visual prosthetics that are intended to create an ar ...

2021-06-23 - Second Sight Medical Products : Announces Proposed Public Offering of Common Stock (Form 8-K)

Second Sight Medical Products Announces Proposed Public Offering of Common Stock Los Angeles, CA - (BUSINESS NEWSWIRE) - June 22, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ('Second Sight' or the 'Company') a leading developer of implantable visual prosthetics that are intended t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.2M0N/A$3M
#2
$45M0N/A$476.3M
#3
N/A0N/AN/A
#4
$14M0N/AN/A
#5
N/A0N/A$175.6M

Second Sight Medical Products Funding

DateAmountRoundLead InvestorsReference
2014-07-03$6.0MUndisclosedArticle
2016-06-02$19.4MUndisclosedBroadridge Corporate Issuer Solutions, IncArticle
2018-05-08$10.0MUndisclosedArticle
2018-10-23$4.0MUndisclosedArticle